Visualizing how cancer drugs reshape proteins linked to lung cancer

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...
Technology Networks

Scientists Uncover New Clues on Lung Cancer Treatment Resistance

Researchers visualized ALK fusion proteins in real time. They showed that ALK inhibitors reshape flexible protein regions to ...
Medical Xpress

Researchers recommend new standard of care for families with hereditary neuroblastoma linked to ALK mutation

Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common ...
Medscape

EML4-ALK as a Predictive Marker for Response to EGFR Therapy

Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...
Medical Xpress

Promising preclinical therapy exploits ALK protein to selectively destroy tumors while sparing healthy cells

Researchers at Children's Hospital of Philadelphia (CHOP) unveiled a novel antibody-drug conjugate (ADC) that shows striking efficacy against cancers that express the anaplastic lymphoma kinase (ALK) ...
Seeking Alpha

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive ...
The American Journal of Managed Care

FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...